← All indications
Cancer Pain
Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.
Drugs by status
Approved for this indication (3)
Phase 4 trials (8)
Phase 3 trials (13)
Organizations
Organization Involved with Phase 4 Indications (15)
- Cephalon
- Mundipharma
- National Cancer Institute (NCI)
- Cukurova University
- Haraldsplass Deaconess Hospital
- University of Bristol
- Fujian Medical University
- Taichung Veterans General Hospital
- Mario Negri Institute
- Yeongnam University
- Catholic University of Korea
- Janssen Pharmaceutica NV
- University of Texas at Houston
- Johnson and Johnson
- Institut Hospital del Mar d'Investigacions Mèdiques
Organization Involved with Phase 3 Indications (85)
- Zars Pharma Inc.
- Archimedes Pharma Ltd
- Grunenthal
- Recordati
- AstraZeneca
- Eli Lilly
- Pfizer
- Akela Pharma, Inc.
- Alza
- GW Pharmaceuticals Ltd.
- Kyowa Hakko Kirin
- Nycomed
- Sorrento Therapeutics, Inc.
- Wex Pharmaceuticals Inc.
- Otsuka
- National Institutes of Health (NIH)
- British Columbia Cancer Agency
- Velindre NHS Trust
- Huazhong University of Science and Technology
- Maastricht University
- Faculdade de Medicina do ABC
- Flinders University
- Hospital de Cancer de Barretos - Fundacao Pio XII
- Hospital Universitario Fundación Alcorcón
- Instituto do Cancer do Estado de São Paulo
- L'Hospitalet de Llobregat
- Monash University
- Norwegian University of Science and Technology
- Seoul National University
- Universidad Autonoma de Madrid
- +55 more
Organization Involved with Phase 2 Indications (18)
- Celgene
- Merck
- Sanofi
- Cubist
- GlaxoSmithKline
- Merz
- MetaPhore Pharmaceuticals
- Korea Research Foundation
- Emory University
- Korea University
- Sheffield Hallam University
- Yale University
- Mayo Clinic
- University of California, San Diego
- University of California, San Francisco
- Dongguk University
- Tetra Bio-Pharma
- Pusan National University
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (10)